US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Quasi-New Stocks

950.96

-2.4317-0.25%

Number of Gainers:70

Number of Losers:101

Number of Flat:9

PE:- -

High:957.81

Open:948.71

Low:930.92

Close:953.43

Volume:796.11M

Turnover:12.44B

Market Cap:695.19B

Float Cap:502.49B

Loading ...

Rani Therapeutics announces debt conversion

Rani Therapeutics Amends Loan Agreement With Avenue, Converts $6 Million Debt Into Equity and Warrants

Rani Therapeutics announces $1.085B collaboration with Chugai Pharmaceutical

BRIEF-Rani Therapeutics Announces Up To $1.085 Billion Collaboration With Chugai Pharmaceutical Co. For Multiple High-Value Therapeutics Including Rare Disease And Immunology Programs And Announces Concurrent Oversubscribed $60.3 Million Financing

Rani Therapeutics Announces Oversubscribed $60.3 Million Private Placement Priced at-the-Market Under Nasdaq Rules

THOMSON REUTERS

Press Release: Rani Therapeutics Announces Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules

Rani Therapeutics Holdings : Chugai Has Option to Extend Rights to Partner With Co on up to 5 Additional Drug Targets

THOMSON REUTERS

Rani Therapeutics Holdings Inc - Announces $60.3 Mln Private Placement Financing

THOMSON REUTERS

Rani Therapeutics Announces up to $1.085 Billion Collaboration With Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 Million Financing

THOMSON REUTERS

Climb Bio presents preclinical data on CLYM116 at ASN Kideny Week

GH Research plc Announces Positive Trial Results for GH001 in Treatment-Resistant Depression, Showing No Increase in Suicidal Ideation or Behavior

Frontier Airlines Expands Service with New Nonstop Flights from Richmond to Atlanta and Denver

Climb Bio Unveils Promising Clinical Data for Budoprutug in Membranous Nephropathy and Preclinical Results for CLYM116 in IgA Nephropathy at ASN Kidney Week 2025

Sight Sciences Announces Fee Schedule Establishment from Novitas Solutions and First Coast Service Options for the TearCare® Interventional Dry Eye Procedure

FIGS (FIGS) Is Up 10.8% After Beating Q2 Estimates and Earning Analyst Praise – Has The Bull Case Changed?

Simply Wall St.

Market Analysis on October 17

Atai Life Sciences 23.725M share Spot Secondary priced at $5.48

Could Dogecoin Be the Next Bitcoin?

Procore’s Strategic AI Integration and Growth Potential Bolster Buy Rating

Zhihu’s Yanyan Story Makes International Debut at Frankfurt Book Fair, Showcasing China’s Short-Form Literature to the World

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4539/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4539","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4539\",,,,,undefined,":{"symbol":"BK4539","market":"US","secType":"PLATE","nameCN":"Quasi-New Stocks","latestPrice":950.99524,"timestamp":1760728655410,"preClose":953.42694,"halted":0,"volume":796073865,"delay":0,"changeRate":-0.00255,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":-2.431702,"latestTime":"10-17 15:17:35 EDT","open":948.70605,"high":957.80756,"low":930.92267,"amount":12441267157.485676,"amplitude":0.028198,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1760731200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":8.337753,"peRate":285.719961,"turnoverRate":0.059539,"increases":70,"decrements":101,"flats":5,"marketCap":695187696152.25,"floatMarketCap":502488101637.625},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4539\",,,,,undefined,":{"symbol":"BK4539","high":957.80756,"amplitude":0.028198,"preClose":953.42694,"low":930.92267,"pbRate":"8.337753","latestPrice":950.95544,"volume":796105935,"delay":0,"open":948.70605,"prevYearClose":648.26935,"prevWeekClose":954.989,"prevMonthClose":1016.6711,"prevQuarterClose":1016.6711,"fiveDayClose":954.989,"twentyDayClose":968.3496,"sixtyDayClose":828.7304,"secType":"PLATE","market":"US","turnoverRate":0.059539,"peRate":285.719961,"marketCap":695187696152.25,"floatMarketCap":502488101637.625,"timestamp":1760728657349,"nameCN":"Quasi-New Stocks"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4539\",,,,undefined,":{"bkCode":"BK4539","up":70,"down":101,"flat":9},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4539\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2576369032","title":"Rani Therapeutics announces debt conversion","url":"https://stock-news.laohu8.com/highlight/detail?id=2576369032","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576369032?lang=en_us&edition=fundamental","pubTime":"2025-10-17 19:40","pubTimestamp":1760701227,"startTime":"0","endTime":"0","summary":"In connection with the private placement, Avenue Venture Opportunities Fund will convert $6M of outstanding debt into 12,500,000 shares of Class A ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rani-therapeutics-announces-debt-conversion-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rani-therapeutics-announces-debt-conversion-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LENZ","BK4007","BK4539"],"gpt_icon":0},{"id":"2576003443","title":"Rani Therapeutics Amends Loan Agreement With Avenue, Converts $6 Million Debt Into Equity and Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2576003443","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576003443?lang=en_us&edition=fundamental","pubTime":"2025-10-17 19:38","pubTimestamp":1760701137,"startTime":"0","endTime":"0","summary":"Rani Therapeutics Holdings Inc. has announced an amendment to its existing Loan and Security Agreement with Avenue Venture Opportunities Fund, L.P. Effective as of September 30, 2025, Avenue has agreed to convert $6.0 million of outstanding loans into 12,500,000 shares of Class A Common Stock  as part of a private placement. Additionally, Avenue will receive warrants to purchase up to 12,500,000 shares of Class A Common Stock  on the same terms as other purchasers. The amendment is part of Rani Therapeutics' ongoing efforts to strengthen its financial position.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rani Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251017:nNDL9zpqGy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","RANI","BK4007"],"gpt_icon":0},{"id":"2576032865","title":"Rani Therapeutics announces $1.085B collaboration with Chugai Pharmaceutical","url":"https://stock-news.laohu8.com/highlight/detail?id=2576032865","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576032865?lang=en_us&edition=fundamental","pubTime":"2025-10-17 19:35","pubTimestamp":1760700941,"startTime":"0","endTime":"0","summary":"Rani Therapeutics (RANI) entered into a Collaboration and License Agreement with Chugai Pharmaceutical (CHGCY) for the development and commercializ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rani-therapeutics-announces-1-085b-collaboration-with-chugai-pharmaceutical-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rani-therapeutics-announces-1-085b-collaboration-with-chugai-pharmaceutical-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","RANI","LENZ","BK4539","BK4139","CHGCY"],"gpt_icon":0},{"id":"2576034915","title":"BRIEF-Rani Therapeutics Announces Up To $1.085 Billion Collaboration With Chugai Pharmaceutical Co. For Multiple High-Value Therapeutics Including Rare Disease And Immunology Programs And Announces Concurrent Oversubscribed $60.3 Million Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2576034915","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576034915?lang=en_us&edition=fundamental","pubTime":"2025-10-17 19:32","pubTimestamp":1760700740,"startTime":"0","endTime":"0","summary":"BRIEF-Rani Therapeutics Announces Up To $1.085 Billion Collaboration With Chugai Pharmaceutical Co. For Multiple High-Value Therapeutics Including Rare Disease And Immunology Programs And Announces Co","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251017:nTUA9CMMBS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","RANI","BK4007"],"gpt_icon":0},{"id":"2576034674","title":"Rani Therapeutics Announces Oversubscribed $60.3 Million Private Placement Priced at-the-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2576034674","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576034674?lang=en_us&edition=fundamental","pubTime":"2025-10-17 19:31","pubTimestamp":1760700660,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251017:nTUA93HRT1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","RANI","BK4007"],"gpt_icon":0},{"id":"2576965034","title":"Press Release: Rani Therapeutics Announces Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2576965034","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576965034?lang=en_us&edition=fundamental","pubTime":"2025-10-17 19:31","pubTimestamp":1760700660,"startTime":"0","endTime":"0","summary":"-- Financing led by Samsara BioCapital, L.P.  with participation. from additional investors, including RA Capital Management, Anomaly,the right to designate one member of the Company's board of directors. The net proceeds from the oversubscribed private placement , together with an initial upfront payment of $10.0 million and the expected technology transfer milestone of $18.0 million from the Collaboration and License Agreement with Chugai Pharmaceuticals Co. Ltd., which was separately announced today, are expected to fund the Company's operations into 2028. The Company intends to use the net proceeds from the private placement to support the continued advancement of the Company's pipeline using the RaniPill platform.\"We are pleased to have priced this additional financing from leading biotech investors, which we believe reflects growing confidence in our strategy. Upon completion, this transaction would meaningfully strengthen our balance sheet and extend our cash runway into 2028, p","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RANI","BK4007","MNQmain","BK4539",".IXIC","BK4232","BK4022","TQQQ","QID","USAW.SI","NVIW.SI","PSQ","LENZ","SQQQ","BK4139","R","TSYW.SI","QLD","NQmain","USJW.SI"],"gpt_icon":1},{"id":"2576981034","title":"Rani Therapeutics Holdings : Chugai Has Option to Extend Rights to Partner With Co on up to 5 Additional Drug Targets","url":"https://stock-news.laohu8.com/highlight/detail?id=2576981034","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576981034?lang=en_us&edition=fundamental","pubTime":"2025-10-17 19:30","pubTimestamp":1760700600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251017:nTUA9CMMBS:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RANI","BK4539","BK4007"],"gpt_icon":0},{"id":"2576644034","title":"Rani Therapeutics Holdings Inc - Announces $60.3 Mln Private Placement Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2576644034","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576644034?lang=en_us&edition=fundamental","pubTime":"2025-10-17 19:30","pubTimestamp":1760700600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251017:nTUA9CMMBS:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RANI","BK4539","BK4007"],"gpt_icon":0},{"id":"2576403462","title":"Rani Therapeutics Announces up to $1.085 Billion Collaboration With Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 Million Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2576403462","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576403462?lang=en_us&edition=fundamental","pubTime":"2025-10-17 19:30","pubTimestamp":1760700600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251017:nTUA9CMMBS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","RANI","BK4539"],"gpt_icon":0},{"id":"2576034822","title":"Climb Bio presents preclinical data on CLYM116 at ASN Kideny Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2576034822","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576034822?lang=en_us&edition=fundamental","pubTime":"2025-10-17 19:15","pubTimestamp":1760699753,"startTime":"0","endTime":"0","summary":"Climb Bio (CLYM) announced the upcoming presentation of CLYM116 preclinical data and published budoprutug pMN Phase 1b long-term outcome data at th...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/climb-bio-presents-preclinical-data-on-clym116-at-asn-kideny-week-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/climb-bio-presents-preclinical-data-on-clym116-at-asn-kideny-week-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CLYM","BK4539"],"gpt_icon":0},{"id":"2576031828","title":"GH Research plc Announces Positive Trial Results for GH001 in Treatment-Resistant Depression, Showing No Increase in Suicidal Ideation or Behavior","url":"https://stock-news.laohu8.com/highlight/detail?id=2576031828","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576031828?lang=en_us&edition=fundamental","pubTime":"2025-10-17 19:03","pubTimestamp":1760699016,"startTime":"0","endTime":"0","summary":"GH Research plc Announces Positive Trial Results for GH001 in Treatment-Resistant Depression, Showing No Increase in Suicidal Ideation or Behavior. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GH Research plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 17, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251017:nNDLDgsDN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","GHRS","BK4539"],"gpt_icon":0},{"id":"2576039083","title":"Frontier Airlines Expands Service with New Nonstop Flights from Richmond to Atlanta and Denver","url":"https://stock-news.laohu8.com/highlight/detail?id=2576039083","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576039083?lang=en_us&edition=fundamental","pubTime":"2025-10-17 19:00","pubTimestamp":1760698840,"startTime":"0","endTime":"0","summary":"Frontier Group Holdings Inc., parent company of Frontier Airlines, has expanded its operations by debuting at Richmond International Airport  with the launch of nonstop service to Hartsfield-Jackson Atlanta International Airport. Additionally, nonstop service to Denver International Airport will begin soon. This expansion provides Richmond travelers with new low-cost options to major cities and strengthens the region's connectivity. Frontier is also introducing new features, including unlimited companion travel for loyal customers and upcoming First Class seating, enhancing the travel experience while maintaining affordable prices.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Frontier Group Holdings Inc. published the original conten","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251017:nNDL22KVv2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4008","BK4539","ULCC","BK4500"],"gpt_icon":0},{"id":"2576033039","title":"Climb Bio Unveils Promising Clinical Data for Budoprutug in Membranous Nephropathy and Preclinical Results for CLYM116 in IgA Nephropathy at ASN Kidney Week 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2576033039","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576033039?lang=en_us&edition=fundamental","pubTime":"2025-10-17 19:00","pubTimestamp":1760698824,"startTime":"0","endTime":"0","summary":"Climb Bio Unveils Promising Clinical Data for Budoprutug in Membranous Nephropathy and Preclinical Results for CLYM116 in IgA Nephropathy at ASN Kidney Week 2025. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief via GlobeNewswire  on October 17, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251017:nNDL9Lh1K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2210150020.SGD","BK4112","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2095319765.USD","BK4588","LU0314104364.USD","IE00B64PRP62.GBP","BK4585","IE00B3QW5Z07.USD","NDAQ","CLYM","LU2210149790.SGD","BK4539"],"gpt_icon":0},{"id":"2576912031","title":"Sight Sciences Announces Fee Schedule Establishment from Novitas Solutions and First Coast Service Options for the TearCare® Interventional Dry Eye Procedure","url":"https://stock-news.laohu8.com/highlight/detail?id=2576912031","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576912031?lang=en_us&edition=fundamental","pubTime":"2025-10-17 19:00","pubTimestamp":1760698800,"startTime":"0","endTime":"0","summary":"MENLO PARK, Calif., Oct.  17, 2025  (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing inn","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/17/3168535/0/en/Sight-Sciences-Announces-Fee-Schedule-Establishment-from-Novitas-Solutions-and-First-Coast-Service-Options-for-the-TearCare-Interventional-Dry-Eye-Procedure.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGHT","BK4082","BK4539"],"gpt_icon":0},{"id":"2576568860","title":"FIGS (FIGS) Is Up 10.8% After Beating Q2 Estimates and Earning Analyst Praise – Has The Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2576568860","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576568860?lang=en_us&edition=fundamental","pubTime":"2025-10-17 18:27","pubTimestamp":1760696869,"startTime":"0","endTime":"0","summary":"Earlier this week, FIGS reported second-quarter results that surpassed analyst expectations and garnered attention as BTIG initiated coverage with a Buy rating, highlighting robust demand in the healthcare apparel sector.\nThis combination of analyst confidence and business outperformance has led to increased discussion of FIGS’ position within a competitive and evolving healthcare apparel market.\nWe'll explore how analyst optimism and strong quarterly earnings could influence FIGS' long-term...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/4131000-choice1-main-header/1585186707756","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/4131000-choice1-main-header/1585186707756"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/consumer-durables/nyse-figs/figs/news/figs-figs-is-up-108-after-beating-q2-estimates-and-earning-a","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/consumer-durables/nyse-figs/figs/news/figs-figs-is-up-108-after-beating-q2-estimates-and-earning-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4202","BK4535","FIGS","BK4561","LU1878469433.USD","BK4198","BK4539"],"gpt_icon":0},{"id":"1102308849","title":"Market Analysis on October 17","url":"https://stock-news.laohu8.com/highlight/detail?id=1102308849","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102308849?lang=en_us&edition=fundamental","pubTime":"2025-10-17 18:22","pubTimestamp":1760696521,"startTime":"0","endTime":"0","summary":"Large-scale collaboration platform for futures trading with SINA offers secure and efficient account opening.\nAccess a wealth of information and precise interpretations through the SINA Finance APP.","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z9Z06.USD","BK4613","LU2063271972.USD","IE00B894F039.SGD","LU1861215975.USD","IE00B19Z9P08.USD","LU2360107168.USD","BK4539","SINA","LU0097036916.USD","LU0353189680.USD","BK4585","APP","BK4608","IE00BZ9MQY76.HKD","LU2250418816.HKD","LU1861220033.SGD","LU1852331112.SGD","LU2087625088.SGD","BK4588","LU2360106780.USD","BK4023","LU2290526834.HKD","LU0056508442.USD"],"gpt_icon":0},{"id":"2576055035","title":"Atai Life Sciences 23.725M share Spot Secondary priced at $5.48","url":"https://stock-news.laohu8.com/highlight/detail?id=2576055035","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576055035?lang=en_us&edition=fundamental","pubTime":"2025-10-17 18:15","pubTimestamp":1760696141,"startTime":"0","endTime":"0","summary":"Atai Life Sciences (ATAI) announced the pricing of a registered underwritten offering of 23.725M common shares, at a price of $5.48 per share. The ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/atai-life-sciences-23-725m-share-spot-secondary-priced-at-5-48-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/atai-life-sciences-23-725m-share-spot-secondary-priced-at-5-48-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ATAI","BK4539","BK4007"],"gpt_icon":0},{"id":"2576036674","title":"Could Dogecoin Be the Next Bitcoin?","url":"https://stock-news.laohu8.com/highlight/detail?id=2576036674","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576036674?lang=en_us&edition=fundamental","pubTime":"2025-10-17 18:15","pubTimestamp":1760696100,"startTime":"0","endTime":"0","summary":"Only one of these cryptocurrencies has staying power.","market":"us","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F837723%2Fgettyimages-1320436824-5.jpg&op=resize&w=165&h=104","type":0,"news_type":0,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F837723%2Fgettyimages-1320436824-5.jpg&op=resize&w=165&h=104"],"rights":{"source":"fool_stock","url":"https://www.fool.com/investing/2025/10/17/could-dogecoin-be-the-next-bitcoin/","rn_cache_url":null,"customStyle":"","selectors":".main-contain, #article-page","filters":"#sticky-wrapper, .navigation, .article-page-end, .foot, .author-tagline, .author-inline, .footer, .soc-share, .wysiwyg, .related-content","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/10/17/could-dogecoin-be-the-next-bitcoin/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["BK4595","BK4588","BK4601","LU1861559042.SGD","BK4585","BK4516","BK4554","MBTmain","LU1861217088.USD","BK4539","BK4112","BK4535","BK4600","BK4596","BK4594","LU1861558580.USD","BK4551","LU2360107671.USD","LU1861220207.SGD"],"gpt_icon":1},{"id":"2576703383","title":"Procore’s Strategic AI Integration and Growth Potential Bolster Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2576703383","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576703383?lang=en_us&edition=fundamental","pubTime":"2025-10-17 17:35","pubTimestamp":1760693750,"startTime":"0","endTime":"0","summary":"William Blair analyst Dylan Becker has reiterated their bullish stance on PCOR stock, giving a Buy rating yesterday. Dylan Becker has given his Buy...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/procores-strategic-ai-integration-and-growth-potential-bolster-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/procores-strategic-ai-integration-and-growth-potential-bolster-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4535","BK4539","BK4023","PCOR"],"gpt_icon":0},{"id":"2576080205","title":"Zhihu’s Yanyan Story Makes International Debut at Frankfurt Book Fair, Showcasing China’s Short-Form Literature to the World","url":"https://stock-news.laohu8.com/highlight/detail?id=2576080205","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576080205?lang=en_us&edition=fundamental","pubTime":"2025-10-17 17:05","pubTimestamp":1760691900,"startTime":"0","endTime":"0","summary":"BEIJING, China, Oct.  17, 2025  (GLOBE NEWSWIRE) -- Zhihu Inc. (“Zhihu” or the “Company”) (NYSE: ZH; HKEX: 2390), a leading online content community in China, debuted its popular Yanyan Story platform","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/17/3168497/0/en/Zhihu-s-Yanyan-Story-Makes-International-Debut-at-Frankfurt-Book-Fair-Showcasing-China-s-Short-Form-Literature-to-the-World.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZH","BK4509","BK4077","BK4539"],"gpt_icon":0}],"pageSize":20,"totalPage":56,"pageCount":3,"totalSize":1117,"code":"91000000","status":"200"}]}}